Gary Robb Biography and Net Worth

Gary Charles Robb serves as Chief Financial Officer, Secretary of the Company. From 2005 to 2011, Mr. Robb served as the Senior Vice President of Operations, Administration and Finance of Fitness Anywhere, Inc., a private fitness equipment and training company with operations in the United States, Europe and Asia. From 2003 to 2005, Mr. Robb was engaged in the private practice of law. From 2000 to 2002, he was Senior Vice President of Citadon, Inc. He also held positions in business development for Nomura Asset Capital Corporation from 1998 to 1999 and in sales and marketing for Legal Research Network, Inc. from 1996 to 1998. From 1992 to 1996, Mr. Robb practiced law at Howard, Rice, Nemerovski, Canady, Falk & Rabkin. Mr. Robb earned a B.A. in English and Political Philosophy from Yale and a J.D. from Harvard Law School.

What is Gary Charles Robb's net worth?

The estimated net worth of Gary Charles Robb is at least $662,724.02 as of December 5th, 2023. Mr. Robb owns 27,602 shares of Corcept Therapeutics stock worth more than $662,724 as of April 23rd. This net worth evaluation does not reflect any other assets that Mr. Robb may own. Additionally, Mr. Robb receives an annual salary of $963,000.00 as CFO at Corcept Therapeutics. Learn More about Gary Charles Robb's net worth.

How old is Gary Charles Robb?

Mr. Robb is currently 61 years old. There are 7 older executives and no younger executives at Corcept Therapeutics. The oldest executive at Corcept Therapeutics is Dr. Joseph K. Belanoff M.D., Co-Founder, President, CEO & Director, who is 67 years old. Learn More on Gary Charles Robb's age.

What is Gary Charles Robb's salary?

As the CFO of Corcept Therapeutics Incorporated, Mr. Robb earns $963,000.00 per year. The highest earning executive at Corcept Therapeutics is Dr. Joseph K. Belanoff M.D., Co-Founder, President, CEO & Director, who commands a salary of $1,820,000.00 per year. Learn More on Gary Charles Robb's salary.

How do I contact Gary Charles Robb?

The corporate mailing address for Mr. Robb and other Corcept Therapeutics executives is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. Corcept Therapeutics can also be reached via phone at (650) 327-3270 and via email at [email protected]. Learn More on Gary Charles Robb's contact information.

Has Gary Charles Robb been buying or selling shares of Corcept Therapeutics?

Gary Charles Robb has not been actively trading shares of Corcept Therapeutics during the last ninety days. Most recently, Gary Charles Robb sold 1,381 shares of the business's stock in a transaction on Tuesday, December 5th. The shares were sold at an average price of $26.27, for a transaction totalling $36,278.87. Following the completion of the sale, the insider now directly owns 27,602 shares of the company's stock, valued at $725,104.54. Learn More on Gary Charles Robb's trading history.

Who are Corcept Therapeutics' active insiders?

Corcept Therapeutics' insider roster includes G. Baker, Jr. (Director), Joseph Belanoff (CEO), William Guyer (Chief Development Officer), Hazel Hunt (Insider), Joseph Lyon (CAO), Sean Maduck (Insider), David Mahoney (Director), Gary Robb (CFO), and Daniel Swisher, Jr. (Director). Learn More on Corcept Therapeutics' active insiders.

Are insiders buying or selling shares of Corcept Therapeutics?

In the last year, insiders at the biotechnology company sold shares 36 times. They sold a total of 300,108 shares worth more than $8,242,381.33. The most recent insider tranaction occured on April, 4th when insider Joseph Douglas Lyon sold 5,443 shares worth more than $141,518.00. Insiders at Corcept Therapeutics own 18.6% of the company. Learn More about insider trades at Corcept Therapeutics.

Information on this page was last updated on 4/4/2024.

Gary Charles Robb Insider Trading History at Corcept Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/5/2023Sell1,381$26.27$36,278.8727,602View SEC Filing Icon  
5/9/2023Sell30,000$23.87$716,100.0033,997View SEC Filing Icon  
11/22/2022Sell4,814$26.03$125,308.4221,329View SEC Filing Icon  
11/17/2022Sell10,000$26.06$260,600.0039,544View SEC Filing Icon  
9/7/2022Sell50,000$26.06$1,303,000.0049,544View SEC Filing Icon  
7/6/2022Sell45,000$26.00$1,170,000.0024,123View SEC Filing Icon  
5/19/2022Sell6,127$19.57$119,905.3936,446View SEC Filing Icon  
5/17/2022Sell28,745$19.55$561,964.7542,701View SEC Filing Icon  
3/17/2022Sell7,512$24.68$185,396.16View SEC Filing Icon  
9/15/2021Sell47,853$20.49$980,507.97View SEC Filing Icon  
9/13/2021Sell6,341$20.89$132,463.49136,507View SEC Filing Icon  
4/23/2021Sell10,000$24.02$240,200.0075,638View SEC Filing Icon  
2/12/2021Sell112,100$28.22$3,163,462.00197,738View SEC Filing Icon  
12/12/2018Sell25,000$19.01$475,250.0021,858View SEC Filing Icon  
5/4/2017Buy5,600$9.75$54,600.006,858View SEC Filing Icon  
See Full Table

Gary Charles Robb Buying and Selling Activity at Corcept Therapeutics

This chart shows Gary Charles Robb's buying and selling at Corcept Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Corcept Therapeutics Company Overview

Corcept Therapeutics logo
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
Read More

Today's Range

Now: $24.01
Low: $22.36
High: $24.23

50 Day Range

MA: $23.89
Low: $21.66
High: $25.74

2 Week Range

Now: $24.01
Low: $20.84
High: $34.28


1,058,055 shs

Average Volume

1,471,441 shs

Market Capitalization

$2.50 billion

P/E Ratio


Dividend Yield